Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Cronos Australia Ltd. ( (AU:VIT) ).
Vitura Health Limited has announced an investor webinar to present its FY2025 financial results, highlighting its strategic initiatives and operational advancements. The company’s focus on integrating digital health solutions, such as the Canview platform and telehealth services, positions it as a leader in the Australian healthcare market, with significant opportunities in the distribution of medicinal cannabis and psychedelic products.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
More about Cronos Australia Ltd.
Vitura Health Limited is a diversified digital health business listed on the ASX, operating through subsidiaries that include Burleigh Heads Cannabis, Canview, Doctors on Demand, Cortexa, Candor Medical, and Flora Holdings. The company focuses on providing a comprehensive healthcare ecosystem, particularly in medicinal cannabis, telehealth services, and psychedelic products for research and therapeutic use in Australia.
Average Trading Volume: 239,854
Technical Sentiment Signal: Sell
Current Market Cap: A$46.69M
For a thorough assessment of VIT stock, go to TipRanks’ Stock Analysis page.